Hänggi et al. investigate how tumor necroptosis regulates anti-tumor immunity and find an unexpected role for interleukin-1α (IL-1α) release by dying cells in promoting tumor growth by driving recruitment and functional alterations of myeloid cells, thereby suppressing T cell effector function at steady-state and during chemotherapy.
Yelena Y. Janjigian, MD, highlights key takeaways and data from 2024 in the gastric and GEJ cancer field.
Pelotonia announced today an annual fundraising total of $26,200,095 in 2024, bringing all-time funds raised to $309,861,962 for innovative cancer research at
Summary:. The conventional wisdom is that the overwhelming majority of neoantigens arise from chromosomal DNA mutations; however, recent studies show that posttranscriptional and posttranslational events…
During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK inhibitors used to treat patients with…
Transposon-engineered BAFF ligand–based CAR T cells induced responses with a tolerable safety profile among 3 patients with relapsed/refractory B-cell NHL.
Seed et al. explore a cohort of PARPi-treated advanced prostate cancers, studying plasma cell-free DNA samples for genomic alterations that provide drug resistance. They find multiple…
A recent study by Ascic et al. demonstrates that in situ reprogramming of tumor cells into conventional dendritic cell (cDC)-like cells using viral-PIB transcription factors…
Following on from the discovery that innate immune pathways are shared widely across the tree of life comes another surprise: Hobbs et al. show that…
A recent article suggested that community doctors lag in precision oncology. Ramy Sedhom, MD, defends the role of these oncologists in personalized cancer care.
